Tylenol Lawsuits Move Forward, As Bernstein Liebhard LLP Notes Issuance of New Order Governing Discovery in Federal Tylenol Products Liability Litigation
New York, New York (PRWEB) January 13, 2014 -- More than 100 Tylenol lawsuit (http://www.tylenollawsuitcenter.com/) claims filed on behalf of individuals who sustained liver damage, allegedly due to their use of a Tylenol brand product, continue to move forward in a multidistrict litigation now underway in U.S. District Court, Eastern District of Pennsylvania, Bernstein Liebhard LLP reports. According to an Order issued on January 7, 2014, the Court has ordered Johnson & Johnson and McNeil Consumer Healthcare to produce any documents in their possession, custody or control that relate to prescription drugs that contain acetaminophen as an ingredient, as well as documents that pertain to liver damage, the prevention of liver damage, and the study of liver damage. However, the Order stipulates that the Defendants are not required to produce any documents pertaining to acetaminophen-based medications if they do not concern the acetaminophen component of a drug, or liver damage. (In Re: Tylenol (Acetaminophen) Marketing, Sales Practices and Products Liability Litigation, MDL No. 2436)
“Our Firm has heard from numerous individuals who suffered serious liver damage, allegedly following use of a Tylenol brand product. This Order will ensure that plaintiffs in Tylenol lawsuits involving liver injury allegations have access to evidence that is relevant to their claims,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is offering free Tylenol lawsuit reviews to victims of severe liver damage allegedly associated with the use of Tylenol-brand medications.
Tylenol Lawsuits
According to court documents, at least 102 Tylenol lawsuits are now pending in the multidistrict litigation underway in the Eastern District of Pennsylvania. All of the lawsuits allege that use of Tylenol-brand over-the-counter medications caused plaintiffs to suffer acetaminophen-induced liver injuries, resulting in hospitalization, liver transplantation, or death, even when the drugs were taken as directed. All of the claims further allege that Johnson & Johnson and McNeil failed to provide consumers with adequate warnings regarding the association between the acetaminophen in Tylenol and liver damage.
According to the U.S. Food & Drug Administration (FDA), acetaminophen was the leading cause of acute liver failure in the U.S. between 1998 and 2003. From 1990 to 1998, acetaminophen was blamed for 56,000 emergency room visits, 26,000 hospitalizations, and 458 deaths annually.* This week, prescription drugs that contain acetaminophen will be subject to new dosage limits imposed by the FDA to reduce the risk of liver damage associated with acetaminophen overdose. According to a notice posted on the Federal Register, the amount of acetaminophen allowed in prescription drugs is being reduced to 325 mg per tablet.
Bloomberg.com reported last August that Johnson & Johnson is in the process of adding more prominent warnings regarding the risk of liver damage to the labels of Tylenol-brand medications. Bottles of Extra Strength Tylenol began to appear with the new label warnings this past October, while other medications in the line are expected to follow. According to Bloomberg, Extra Strength Tylenol caplets each contain 500 mg of acetaminophen, well over the new limits set by the FDA.**
Victims of serious liver damage resulting in hospitalization, liver transplantation, or death, may be entitled to compensation from Johnson & Johnson and McNeil Consumer Healthcare. To learn more about filing a Tylenol lawsuit, please visit Bernstein Liebhard LLP’s website. To arrange for a free legal review, please call 800-511-5092.
*fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/DrugSafetyandRiskManagementAdvisoryCommittee/UCM164897.pdf, FDA, 2009
**bloomberg.com/news/2013-08-29/j-j-adds-warning-to-tylenol-caps-on-acetaminophen-risk.html, Bloomberg.com, August 29, 2013
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 11 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
800-511-5092
ATTORNEY ADVERTISING. © 2014 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, 800-511-5092. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Contact Information:
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info(at)consumerinjurylawyers(dot)com
http://www.tylenollawsuitcenter.com/
https://plus.google.com/115936073311125306742?rel=author
Felecia L. Stern, Tylenol Lawsuit Information Center, http://www.tylenollawsuitcenter.com/, +1 800-511-5092, [email protected]
Share this article